65,437 trials
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI, Average Number of Events for Every Hour of Sleep) — 20.8; 24.4; 18.8; 14 events/hour of sleep — p=>0.5
Dengue Fever
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies (Microneutralization Test [MNT50]) for Each of the Four DENV Serotypes for Participants in the Immunogenicity…
Melanoma (Skin)
Primary: Objective Response Rate Among KIT-positive Patients — 0.182 proportion of participants
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
Non-small Cell Lung Carcinoma · Small Cell Lung Carcinoma
Primary: Number of Participants With Grade 3 or Higher Acute Esophagitis (CTCAE) — 0 Participants
Type 1 Diabetes
Primary: Feasibility of Study Design — 84; 84 Participants
Myopia
Primary: Change in Refractive Error Relative to Baseline — -0.18; -0.58 Diopters
Tobacco Use Disorder · Smoking
Primary: Changes in the Number of Cigarettes Per Day (CPD) — 8.2; 7.3 cigarettes per day (CPD)
Healthy Volunteers
Primary: Absolute Bioavailability of Oral Balovaptan at Dose Level A (Cohort 1) — 100.6 Percentage
Myopia · Hyperopia
Primary: Accuracy of Assessment of Participants' Best Visual Acuity (in Diopters) — 0.685; -0.416; -0.039 Diopters
Metastatic Melanoma
Primary: Number of Reported Adverse Events — 124; 89; 35 Treatment related adverse events
Anemia, Iron-Deficiency · Inflammatory Bowel Disease · Crohn's Disease
Primary: Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12 — 84; 105; 41; 20 Participants — p=0.298
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year